After hitting record high in previous session, Caplin Point shares slip over 4%

On Monday, shares rallied as the company informed bourses that ANVISA-Brazil conducted an inspection of Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi, and the inspection concluded with zero observations.

The inspection was conducted between August 12 and 16, 2024, the company said.

Chairman CC Paarthipan added, “It is indeed gratifying to have two back-to-back audits with zero observations. We remain steadfast in our commitment to maintaining the highest levels of quality compliance at all our sites. Brazil is an important part of our expansion plans in Latin America, and this clearance opens the door to the largest market in that geography.”

As per news reports, Caplin Point’s net profit rose 20% to ₹124 crore in the June quarter of financial year 2025, from ₹103.4 crore logged in the same quarter a year ago (Q1FY24). The company’s revenue from operations surged 16% year-on-year (Y-o-Y) to ₹459 crore during the quarter under review, from ₹395.3 crore registered in the June quarter of FY24.

About Caplin Point Labs

The company was incorporated on April 16, 1990. It is in the business of pharmaceuticals, such as producing, developing, and marketing a wide range of generic formulations and branded products and exporting them to overseas markets. Its main research and development facilities are located in Tamil Nadu, and it has a manufacturing plant in Puducherry.

Caplin Point stock performance

Shares of the company have surged 70.59% over the past 12 months and 336% in the last five years. In comparison, the NIFTY PHARMA index has rallied nearly 46% in one year and 187% in five years.